Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C5H6NO3.Zn |
| Molecular Weight | 321.621 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Zn++].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]2CCC(=O)N2
InChI
InChIKey=OWVLYQRCCIEOPF-QHTZZOMLSA-L
InChI=1S/2C5H7NO3.Zn/c2*7-4-2-1-3(6-4)5(8)9;/h2*3H,1-2H2,(H,6,7)(H,8,9);/q;;+2/p-2/t2*3-;/m00./s1
| Molecular Formula | C5H6NO3 |
| Molecular Weight | 128.106 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Zn |
| Molecular Weight | 65.409 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.currentscience.ac.in/Volumes/102/02/0288.pdfhttps://www.drugs.com/otc/121041/cleansing-foaming-gel-acne-pro-skin.html | https://www.ncbi.nlm.nih.gov/pubmed/25727335 | https://www.ncbi.nlm.nih.gov/pubmed/21834944 | https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean | http://www.scalp-health.com/zinc-pca.htmCurator's Comment: description was created based on several sources, including
http://www.cir-safety.org/sites/default/files/pca.pdf
Sources: http://www.currentscience.ac.in/Volumes/102/02/0288.pdfhttps://www.drugs.com/otc/121041/cleansing-foaming-gel-acne-pro-skin.html | https://www.ncbi.nlm.nih.gov/pubmed/25727335 | https://www.ncbi.nlm.nih.gov/pubmed/21834944 | https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean | http://www.scalp-health.com/zinc-pca.htm
Curator's Comment: description was created based on several sources, including
http://www.cir-safety.org/sites/default/files/pca.pdf
Zinc Pidolate (Zinc PCA) is a topical skin product with purifying, astingent, anti-inflammatory, antiseptic activity. It has long been used as a cosmetic ingredient, because of its astringent and anti-microbial properties. Zinc Pidolate has also being shown to be effective against halitosis. Zinc PCA prevents the UV-induced MMP-1 production in vitro by suppressing the activation of AP-1. Zinc PCA was also able to enhance type I collagen synthesis in NHDFs, by increasing the expression of the mRNA encoding the ascorbic acid transporter SVCT2 in non-UV irradiated
NHDFs, which suggests its promising effect against not only photoaged skin but also for the simple atrophic change of intrinsic skin ageing. Zinc PCA is able to suppress sebum secretion by inhibiting 5-α reductase in hyperseborrhea, to suppress body odor by forming zinc salts with short-chain fatty acids, to suppress wrinkles by inhibiting AP-1 to and inhibit bacterial growth including acne related Propionibacterium acnes.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3271 |
|||
Target ID: P02452|||Q15176|||Q9UML6 Gene ID: 1277.0 Gene Symbol: COL1A1 Target Organism: Homo sapiens (Human) |
|||
Target ID: CHEMBL2111421 |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | CLEANSING FOAMING GEL ACNE PRO SKIN- zinc pidolate gel Approved UseLange Gel will turn into foam, during application. It will cleanse skin thoroughly without any dryness effect, in order to avoid hyperseboohea phenomenon, a main cause of acne. Launch Date2012 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | EcoCare™ Zinclean Approved UseUse in anti-dandruff shampoos |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Human seminal relaxin is a product of the same gene as human luteal relaxin. | 1992 May |
|
| Characterizing degradation products of peptides containing N-terminal Cys residues by (off-line high-performance liquid chromatography)/matrix-assisted laser desorption/ionization quadrupole time-of-flight measurements. | 2003 |
|
| Determination of the post-translational modifications of salivary acidic proline-rich proteins. | 2003 Apr |
|
| Pressure/temperature combined treatments of precursors yield hormone-like peptides with pyroglutamate at the N terminus. | 2003 Dec 31 |
|
| [Characteristics of pyrrolidone pharmacokinetics in rats]. | 2003 Nov-Dec |
|
| Origin of diastereoselection in the hydrosilylation of chiral N-acyliminium intermediates derived from pyroglutamic acid. | 2004 Apr 26 |
|
| Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. | 2004 Apr 9 |
|
| Glutamine in commercial liquid nutritional products. | 2004 Aug 11 |
|
| Toward the synthesis of pyroglutamate lauroyl ester: biocatalysis versus chemical catalysis. | 2004 Feb |
|
| Stabilization of peptide guinea pig myelin basic protein 72-85 by N-terminal acetylation-implications for immunological studies. | 2004 Feb |
|
| Expression, purification, and characterization of avian Thy-1 from Lec1 mammalian and Tn5 insect cells. | 2004 Feb |
|
| Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site. | 2004 Feb 10 |
|
| Identification of endogenous phosphorylation sites of bovine medium and low molecular weight neurofilament proteins by tandem mass spectrometry. | 2004 Feb 24 |
|
| N-acetylation of the glutamate residue of intact glutathione conjugates in rats: a novel pathway for the metabolic processing of thiol adducts of xenobiotics. | 2004 Jan |
|
| Integrative annotation of 21,037 human genes validated by full-length cDNA clones. | 2004 Jun |
|
| Chemical characterization of a lambda I amyloid protein isolated from formalin-fixed and paraffin-embedded tissue sections. | 2004 Mar |
|
| Unexplained metabolic acidosis in critically ill patients: the role of pyroglutamic acid. | 2004 Mar |
|
| Synthesis of (2S,3S)-3'-fluoroisoleucine. | 2004 Mar 7 |
|
| Skin secretion of the toad Bombina variegata contains multiple insulin-releasing peptides including bombesin and entirely novel insulinotropic structures. | 2004 Mar-Apr |
|
| Mass spectrometric analysis of posttranslational modifications of a carrot extracellular glycoprotein. | 2004 May 25 |
|
| Synthesis of (2S,3R)-[3',3',3'-2H3]-valine and (2S,3S)-4-fluorovaline. | 2004 May 7 |
|
| Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity. | 2004 May-Jun |
|
| Discrepin, a new peptide of the sub-family alpha-ktx15, isolated from the scorpion Tityus discrepans irreversibly blocks K+ -channels (IA currents) of cerebellum granular cells. | 2004 Oct 15 |
|
| Alpha-tocopherol pro-vitamins: synthesis, hydrolysis and accumulation in rabbit ear skin. | 2004 Oct 19 |
|
| Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions. | 2004 Sep |
|
| Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)). | 2004 Sep |
|
| The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. | 2004 Sep 21 |
|
| Mass spectrometry analysis of recombinant human ZP3 expressed in glycosylation-deficient CHO cells. | 2004 Sep 28 |
|
| A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition. | 2005 |
|
| The computer modelling of human TRH receptor, TRH and TRH-like peptides. | 2005 |
|
| Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes. | 2005 Apr |
|
| Emerging roles of apelin in biology and medicine. | 2005 Aug |
|
| Formation of extracellular glutamate from glutamine: exclusion of pyroglutamate as an intermediate. | 2005 Aug 2 |
|
| Nanoparticles on the basis of highly functionalized dextrans. | 2005 Aug 3 |
|
| Stereoselective synthesis of conformationally constrained omega-amino acid analogues from pyroglutamic acid. | 2005 Aug 7 |
|
| Physiological and pathological aspects of GSH metabolism. | 2005 Feb |
|
| Acetaminophen-induced anion gap metabolic acidosis and 5-oxoprolinuria (pyroglutamic aciduria) acquired in hospital. | 2005 Jul |
|
| Recurrent high anion gap metabolic acidosis secondary to 5-oxoproline (pyroglutamic acid). | 2005 Jul |
|
| Identification of novel bradykinin-potentiating peptides and C-type natriuretic peptide from Lachesis muta venom. | 2005 Jul |
|
| The removal of pyroglutamic acid from monoclonal antibodies without denaturation of the protein chains. | 2005 Jul 1 |
|
| CLPM: a cross-linked peptide mapping algorithm for mass spectrometric analysis. | 2005 Jul 15 |
|
| Total synthesis of pinnamine and anatoxin-a via a common intermediate. A caveat on the anatoxin-a endgame. | 2005 Jul 8 |
|
| Preparation and reactivity of aminoacyl pyroglutamates. Facile synthesis of 10-membered-ring cyclic dipeptides derived from 1,4-diaminobutyric and glutamic acids. | 2005 Mar |
|
| Bromophenols coupled with derivatives of amino acids and nucleosides from the red alga Rhodomela confervoides. | 2005 May |
|
| Biomarker metabolites capturing the metabolite variance present in a rice plant developmental period. | 2005 May 31 |
|
| Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan AND A{beta}) in the absence of compact plaques. | 2005 Nov 4 |
|
| Cloning, expression, characterization, and crystallization of a glutaminyl cyclase from human bone marrow: a single zinc metalloenzyme. | 2005 Sep |
|
| Synthesis of 1,3-dioxo-hexahydropyrido[1,2-c][1,3]diazepine carboxylates, a new bicyclic skeleton formed by ring expansion-RCM methodology. | 2005 Sep 21 |
|
| Thermostability and in vitro digestibility of a purified major allergen 2S albumin (Ses i 1) from white sesame seeds (Sesamum indicum L.). | 2005 Sep 25 |
|
| CFSUM1 and CFSUM2 in urine from patients with chronic fatigue syndrome are methodological artefacts. | 2006 Feb |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:38:28 GMT 2025
by
admin
on
Mon Mar 31 19:38:28 GMT 2025
|
| Record UNII |
C32PQ86DH4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11602214
Created by
admin on Mon Mar 31 19:38:28 GMT 2025 , Edited by admin on Mon Mar 31 19:38:28 GMT 2025
|
PRIMARY | |||
|
C32PQ86DH4
Created by
admin on Mon Mar 31 19:38:28 GMT 2025 , Edited by admin on Mon Mar 31 19:38:28 GMT 2025
|
PRIMARY | |||
|
SUB26632
Created by
admin on Mon Mar 31 19:38:28 GMT 2025 , Edited by admin on Mon Mar 31 19:38:28 GMT 2025
|
PRIMARY | |||
|
DTXSID40935009
Created by
admin on Mon Mar 31 19:38:28 GMT 2025 , Edited by admin on Mon Mar 31 19:38:28 GMT 2025
|
PRIMARY | |||
|
15454-75-8
Created by
admin on Mon Mar 31 19:38:28 GMT 2025 , Edited by admin on Mon Mar 31 19:38:28 GMT 2025
|
PRIMARY | |||
|
DBSALT001565
Created by
admin on Mon Mar 31 19:38:28 GMT 2025 , Edited by admin on Mon Mar 31 19:38:28 GMT 2025
|
PRIMARY | |||
|
100000090155
Created by
admin on Mon Mar 31 19:38:28 GMT 2025 , Edited by admin on Mon Mar 31 19:38:28 GMT 2025
|
PRIMARY | |||
|
1426280
Created by
admin on Mon Mar 31 19:38:28 GMT 2025 , Edited by admin on Mon Mar 31 19:38:28 GMT 2025
|
PRIMARY | RxNorm | ||
|
C32PQ86DH4
Created by
admin on Mon Mar 31 19:38:28 GMT 2025 , Edited by admin on Mon Mar 31 19:38:28 GMT 2025
|
PRIMARY | |||
|
239-473-5
Created by
admin on Mon Mar 31 19:38:28 GMT 2025 , Edited by admin on Mon Mar 31 19:38:28 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
||
|
|
PARENT -> SALT/SOLVATE |
|
